Understanding how cancer cells' genomic instability affects immune responses

Genome Instability Induced Anti-Tumor Immune Responses

NIH-funded research University of Pennsylvania · NIH-11085247

This study is looking at how damage in cancer cells can alert the immune system to fight tumors better, and it's for anyone interested in new ways to improve cancer treatments.

Quick facts

Grant typeP01 program project
Study typeNIH-funded research
Funding institutionUniversity of Pennsylvania NIH-funded
Lab location1 site (Philadelphia, United States)
Project IDNIH-11085247 on NIH RePORTER

What this research studies

This research investigates how genomic instability in cancer cells can trigger immune responses that may help fight tumors. The team will explore how DNA damage and changes in cell structure can be recognized by the immune system as foreign threats. By studying these interactions, the researchers aim to uncover new ways to enhance anti-tumor immunity and improve cancer treatment strategies. The project consists of three interconnected projects that will analyze different aspects of this relationship in both laboratory and live tumor environments.

Who could benefit from this research

Good fit: Ideal candidates for this research are patients with tumors exhibiting genomic instability, which may include various types of cancers.

Not a fit: Patients with stable tumors that do not exhibit genomic instability may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to new immunotherapy strategies that better harness the body's immune system to combat cancer.

How similar studies have performed: Previous research has shown promising results in understanding the immune system's response to genomic instability, suggesting that this approach could lead to significant advancements in cancer treatment.

Where this research is happening

Philadelphia, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions anti-cancer immunotherapyanticancer immunotherapy
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.